The global Neurological Biomarkers Market Growth Accelerated by Increased Adoption of Personalized Medicine
![]() |
Neurological Biomarkers Market |
Neurological
biomarkers help in early diagnosis and better management of neurological
diseases like Alzheimer's disease, Parkinson's disease and various types of
brain cancer. Biomarkers play an important role in developing personalized
treatment strategies. The growing focus on precision medicine is driving the
demand for neurological biomarkers to develop targeted therapies. Biomarkers
help identify individuals who are more likely to benefit from specific drugs
and therapies. This is accelerating the adoption of personalized treatment
approaches.
The
global Neurological Biomarkers Market is estimated to be valued at US$ 11813.64
Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period
2023 to 2030, as highlighted in a new report published by Coherent Market
Insights.
Market key trends:
The increased adoption of personalized medicine is one of the key trends in the
neurological biomarkers market. Biomarkers help develop personalized treatment
regimens by identifying individuals who are more likely to benefit or
experience side-effects from certain therapies. This enables the development of
targeted drugs specific to genetic subtypes of neurological conditions. For
instance, cerebrospinal fluid (CSF) biomarkers like tau and amyloid beta have
emerged as potential biomarkers for early diagnosis and personalized treatment
of Alzheimer's disease. Biomarkers help optimize treatment selection and
facilitate stratified clinical trials. This is driving the demand for
neurological biomarkers from pharmaceutical companies for precision medicine
applications.
Segment Analysis
The global Neurological Biomarkers market is dominated by protein biomarkers
sub segment. Protein biomarkers are diagnostic and prognostic indicators of
various neurological disorders including Alzheimer's disease, Parkinson's
disease, traumatic brain injuries, and stroke. They play a crucial role in drug
development and clinical trials by aiding early diagnosis and helping monitor
disease progression and treatment response. Increased focus on development of
cost-effective and non-invasive protein biomarkers is expected to drive the sub
segment growth over the forecast period.
Key Takeaways
The Global
Neurological Biomarkers Market Share is expected to witness high growth
over the forecast period of 2023 to 2030. The market is driven by rising
prevalence of neurological disorders, growing geriatric population, and
increasing R&D investments in biomarkers. The global Neurological
Biomarkers Market is estimated to be valued at US$ 11813.64 Mn in 2023 and is
expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030.
Regional analysis: North America is currently the dominant region for the
Neurological Biomarkers market owing to rising cases of Alzheimer's,
Parkinson's diseases and favorable regulatory scenario for biomarker
development. However, Asia Pacific region is expected to grow at the fastest
rate over the forecast period supported by rapidly developing healthcare
infrastructure, increasing healthcare expenditure and growing focus of key
players in the region.
Key players: Key players operating in the Neurological Biomarkers market are
Knauf Gips KG, LafargeHolcim, National Gypsum Company, Saint-Gobain Group,
Yoshino Gypsum Co., Ltd., ACG Materials, Anhydritec, BNZ Materials Inc.,
American Gypsum, Gyptec Iberica. These players are focusing on new product
launches, collaborations and geographic expansions to gain market share.
For more insights, Read- https://www.insightprobing.com/neurological-biomarkers-market-size-and-share-2/
Comments
Post a Comment